GSK ploughs on despite second complete response letter for MenHibrix combi vaccine
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline said it remains committed to making its meningococcal and Haemophilus influenzae type b (Hib) combination vaccine, MenHibrix (Hib-MenCY-TT), available in the US despite receiving a second complete response letter from the FDA for its BLA for the product.